Syndax Pharmaceuticals (SNDX)
(Delayed Data from NSDQ)
$9.98 USD
+0.06 (0.60%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $9.98 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
SNDX 9.98 +0.06(0.60%)
Will SNDX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for SNDX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for SNDX
All You Need to Know About Syndax (SNDX) Rating Upgrade to Buy
Earnings Preview: Jazz Pharmaceuticals (JAZZ) Q2 Earnings Expected to Decline
SNDX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Wall Street Analysts Predict a 237.83% Upside in Syndax (SNDX): Here's What You Should Know
Wall Street Analysts See a 219.98% Upside in Syndax (SNDX): Can the Stock Really Move This High?
Syndax Pharmaceuticals (SNDX) Reports Q1 Loss, Tops Revenue Estimates
Other News for SNDX
Syndax Pharmaceuticals (SNDX) Anticipates Q2 Earnings Announcement
Syndax Pharmaceuticals Q2 2025 Earnings Preview
Syndax Pharmaceuticals's Earnings: A Preview
Franklin Biotechnology Discovery Fund Q2 2025 Commentary
Syndax to Announce Second Quarter 2025 Financial Results and Host Conference Call and Webcast ...